1. Home
  2. YMAB

YMAB

Y-mAbs Therapeutics Inc.

Logo Y-mAbs Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Founded: 2015 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 652.7M IPO Year: 2018
Target Price: $15.86 AVG Volume (30 days): 390.7K
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.49 EPS Growth: N/A
52 Week Low/High: $4.60 - $20.90 Next Earning Date: 05-06-2024
Revenue: $84,819,000 Revenue Growth: 29.96%
Revenue Growth (this year): 18.22% Revenue Growth (next year): 18.58%

Share on Social Networks: